Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Organogenesis Holdings Inc (NASDAQ: ORGO) closed at $4.6 in the last session, up 2.00% from day before closing price of $4.51. In other words, the price has increased by $2.00 from its previous closing price. On the day, 0.74 million shares were traded. ORGO stock price reached its highest trading level at $4.685 during the session, while it also had its lowest trading level at $4.48.
Ratios:
We take a closer look at ORGO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.67 and its Current Ratio is at 4.12. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when Freedman Lori bought 142,379 shares for $2.91 per share. The transaction valued at 413,625 led to the insider holds 837,437 shares of the business.
Freedman Lori bought 100,863 shares of ORGO for $284,716 on Jun 04 ’25. The Chief Admin. and Legal Officer now owns 695,058 shares after completing the transaction at $2.82 per share. On Jun 06 ’25, another insider, Freedman Lori, who serves as the Chief Admin. and Legal Officer of the company, bought 9,022 shares for $2.99 each. As a result, the insider paid 26,949 and bolstered with 846,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 583528384 and an Enterprise Value of 641361280. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.27 while its Price-to-Book (P/B) ratio in mrq is 2.40. Its current Enterprise Value per Revenue stands at 1.398 whereas that against EBITDA is 28.467.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.76, which has changed by 0.7760618 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is 20.90%, while the 200-Day Moving Average is calculated to be 20.02%.
Shares Statistics:
According to the various share statistics, ORGO traded on average about 1.20M shares per day over the past 3-months and 744440 shares per day over the past 10 days. A total of 126.85M shares are outstanding, with a floating share count of 64.15M. Insiders hold about 49.43% of the company’s shares, while institutions hold 53.71% stake in the company. Shares short for ORGO as of 1752537600 were 9731517 with a Short Ratio of 8.11, compared to 1749772800 on 10806635. Therefore, it implies a Short% of Shares Outstanding of 9731517 and a Short% of Float of 22.309999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is $0.14, with high estimates of $0.14 and low estimates of $0.14.
Analysts are recommending an EPS of between $0.16 and $0.16 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.23, with 1.0 analysts recommending between $0.23 and $0.23.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $104.75M. It ranges from a high estimate of $106.1M to a low estimate of $103.4M. As of the current estimate, Organogenesis Holdings Inc’s year-ago sales were $130.23MFor the next quarter, 2 analysts are estimating revenue of $137.95M. There is a high estimate of $145.9M for the next quarter, whereas the lowest estimate is $130M.
A total of 2 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $484.5M, while the lowest revenue estimate was $484M, resulting in an average revenue estimate of $484.25M. In the same quarter a year ago, actual revenue was $482.04MBased on 2 analysts’ estimates, the company’s revenue will be $531.15M in the next fiscal year. The high estimate is $539.8M and the low estimate is $522.5M.
